Clevudine for chronic hepatitis B: Antiviral response, predictors of response, and development of myopathy

Journal of Viral Hepatitis

Volumn 18, Issue 2, 2011, Pages 84-90

  Jang, J H ^a   Kim, J W ^a   Jeong, S H ^a   Myung, H J ^a   Kim, H S ^a   Park, Y S ^a   Lee, S H ^a   Hwang, J H ^a   Kim, N ^a   Lee, D H ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

chronic hepatitis B; clevudine; myopathy; resistance; virologic response

Indexed keywords

ADEFOVIR; CLEVUDINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RELAPSE; SEROLOGY; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS LOAD;

EID: 78751474657     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01281.x     Document Type: Article

References (14)

1. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150: 104-110.
2. Ayoub WS, Keeffe EB,. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008; 28: 167-177.
3. Inada M, Yokosuka O,. Current antiviral therapies for chronic hepatitis B. Hepatol Res 2008; 38: 535-542.
4. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172-1178.
5. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007; 46: 1041-1048.
6. Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009; 49: 2080-2086.
7. Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009; 51: 829-834.
8. Fleischer RD, Lok ASF,. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009. doi:.
9. Hussain M, Fung S, Libbrecht E, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006; 44: 1094-1097.
10. Lee KS, Byun KS, Chung YH, et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology 2007; 50: 296-302.
11. Hass HG, Bock T, Nehls O, Kaiser S,. Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. J Gastroenterol 2009; 44: 871-877.
12. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL,. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46: 1695-1703.
13. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
14. Koh KH, Kang CJ, Kim DH, et al. Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B. Korean J Gastroenterol 2008; 52: 325-328.